Every 8-K that Imunon, Inc. (IMNN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow IMNN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IMNN filings page.
Imunon, Inc. (IMNN) entered an Exchange Agreement with Streeterville Capital, LLC under which $1,200,000 of principal under its A-1 Note, together with accrued and unpaid interest, will be exchanged for 120 shares of Series B preferred stock at $10,000 per share. Upon the exchange, Imunon’s obligations under the A-1 Note will be reduced by the principal and interest exchanged; the note otherwise remains in full force and effect.
Imunon designated 200 Series B shares, effective upon filing. Each share has a $12,000 stated value and accrues an 8% annual return, payable in cash or additional Series B shares; it is not convertible into common stock or any other class or series of Imunon stock. Subject to the designation’s terms, Imunon may redeem all or part of the outstanding Series B shares from holders of Series A preferred stock by paying cash equal to 110% of the applicable liquidation amount. Following an event of default, the return would increase by 15% per year. Holders have no voting rights except on matters materially and adversely affecting Series B rights or as required by law.
Imunon, Inc. approved new stock-based compensation elections for senior executives, allowing part of their base salaries to be paid in common stock instead of cash. The President and Chief Executive Officer, Stacy Lindborg, may receive up to 50% of base salary in shares, with additional shares equal to 12% of the aggregate dollar amount of the net stock payment, amended to 35% for shares issuable on August 14 and to 17.5% for shares issuable on each pay date from August 28, 2026 through September 25, 2026. Executive Chairman Michael Tardugno may elect up to 100% of base salary in shares, with additional shares equal to 20% for July 31 issuances, 40% for August 14, and 20% for each pay date from August 28, 2026 through September 25, 2026. Chief Medical Officer Douglas Faller may elect up to 40% of base salary in shares, with additional shares equal to 12% of the net stock payment, amended to 15% for each pay date from July 31, 2026 through September 25, 2026. Shares for Dr. Lindborg and Mr. Tardugno are treated as private offerings under Section 4(a)(2) of the Securities Act, while shares for Dr. Faller will be issued under the Imunon, Inc. 2018 Stock Incentive Plan.
Imunon, Inc. reported financial results for the three and six months ended June 30, 2026 and highlighted progress in its lead DNA-based immunotherapy IMNN-001 for newly diagnosed advanced ovarian cancer. Management reported that enrollment in the pivotal Phase 3 OVATION 3 study is exceeding planning assumptions and is supported by prior Phase 2 data showing a clinically meaningful overall survival benefit. New preliminary data from an ongoing Phase 2 minimal residual disease study showed deeper antitumor responses, including higher circulating tumor DNA clearance and no evidence of disease following frontline therapy in treated patients.
For the second quarter of 2026, net loss was $2.8 million, or $0.54 per share, with operating expenses of $2.8 million. For the first half of 2026, net loss was $7.1 million, or $1.38 per share, on operating expenses of $7.1 million. Research and development expenses increased while general and administrative expenses declined versus 2025. Net cash used in operating activities for the first half of 2026 was $7.0 million, and cash and cash equivalents were $6.9 million as of June 30, 2026, with total liabilities of $10.8 million and stockholders’ equity of $4.2 million.
Imunon, Inc. announced that interim Chief Financial Officer Jeffrey Church plans to retire from his role effective July 1, 2026. To support continuity, he will remain with the company as a consultant under an amended agreement with a $10,000 monthly retainer, cancellable on two business days’ notice.
Effective the same date, Imunon appointed Josh Blacher as its new interim Chief Financial Officer through a master services agreement with Danforth Health, Inc. Imunon will pay Danforth $475 per hour for his CFO services. The filing notes Mr. Church’s departure is due to retirement and not related to any disagreement with management, and confirms that Mr. Blacher has no disclosed related-party relationships or conflicts.
Imunon, Inc. held its 2026 Annual Meeting of Stockholders, where shareholders approved an amendment to the 2018 Stock Incentive Plan to add 1,000,000 shares of common stock, bringing the plan’s aggregate share limit to 1,265,004 shares.
Shareholders elected two Class I directors, Frederick J. Fritz and Christine A. Pellizzari, to serve until the 2029 annual meeting. They also ratified WithumSmith + Brown, PC as independent registered public accounting firm for the fiscal year ending December 31, 2026 and approved, on an advisory basis, 2025 executive compensation.
As of the record date, 3,983,342 shares of common stock were outstanding and entitled to vote, and 1,808,666 shares were represented in person or by proxy at the meeting, constituting a quorum.
Imunon, Inc. entered into a $10 million structured financing with Streeterville Capital that combines non-convertible preferred stock and secured promissory notes to support its clinical programs. The company issued 250 Series A Preferred shares at $10,000 each for $2.5 million and two secured notes with principal amounts of $2.72 million and $5 million. Imunon received $10 million at closing, placing $5 million in a cash collateral account securing the notes and retaining $5 million for corporate uses, including research and development, capital expenditures and working capital. The notes carry interest of 8% and 5%, mature in 18 months, include monthly redemption and prepayment features, and are secured by substantially all company assets other than intellectual property. The Series A Preferred Stock has a stated value of $12,000 per share with an 8% annual return, no conversion to common stock, limited voting rights, and company and holder redemption rights with premiums and default step-ups.
IMUNON, Inc. reported a first quarter 2026 net loss of $4.3 million, or $0.84 per share, compared with a net loss of $4.1 million, or $3.15 per share, a year earlier. Operating expenses rose slightly to $4.3 million, driven mainly by research and development spending of $2.3 million as the company advances its OVATION 3 Phase 3 trial in advanced ovarian cancer. General and administrative costs were stable at $2.0 million.
Net cash used in operations was $4.0 million, and cash and cash equivalents totaled $4.8 million as of March 31, 2026. IMUNON highlighted final Phase 2 OVATION 2 data showing a 14.7‑month median overall survival increase with IMNN‑001 versus standard chemotherapy, and a 24.2‑month median overall survival increase when combined with standard chemotherapy and PARP inhibitors. The FDA has reviewed and is aligned with the Phase 3 protocol for IMNN‑001, confirming a path to a future BLA filing.
Imunon, Inc. entered into change of control agreements with its Chief Executive Officer and President Stacy Lindborg, Chief Medical Officer Douglas Faller, and General Counsel and Corporate Secretary Susan Eylward. These agreements define severance benefits if employment ends in connection with a corporate change in control.
If terminated without cause or leaving for good reason on or within one year after or four months before a change in control, Dr. Lindborg receives a lump sum of 2.5 times her annual base salary plus target bonus, while Dr. Faller and Ms. Eylward receive 1.5 times that sum. Imunon will also cover COBRA health and life insurance premiums for up to eighteen months for the two officers and twenty-four months for Dr. Lindborg, and fully accelerate their outstanding equity awards, subject to a release of claims.
IMUNON, Inc. reported 2025 results and highlighted major advances in its ovarian cancer program. Final Phase 2 OVATION 2 data showed IMNN‑001 plus standard chemotherapy improved median overall survival to 45.1 months versus 30.4 months, and to 65.6 months versus 41.4 months when combined with PARP inhibitor maintenance, improvements the company describes as clinically meaningful.
Enrollment in the pivotal Phase 3 OVATION 3 trial remains ahead of plan. For 2025, IMUNON recorded a net loss of $14.5 million (vs. $18.6 million in 2024) as operating expenses fell 23% to $14.7 million, driven by lower R&D spending as earlier trials wound down. Year-end cash and cash equivalents were $8.8 million, supported by $17.1 million of 2025 financing, including a $7.0 million registered direct offering.
Imunon, Inc. filed a prospectus supplement to register an additional $7,000,000 of common stock under its at-the-market offering program with H.C. Wainwright & Co.
This increases the aggregate amount covered by the program to $17,000,000 of shares. Before this update, the company had already sold $4,797,848 of common stock through the sales agent under the existing agreement.
Imunon, Inc. announced that Executive Vice President and Chief Scientific Officer Khursheed Anwer will retire from the company, with his employment ending on February 20, 2026. His departure is described as being without any disagreements with management.
To support continuity, Imunon and Dr. Anwer entered into a Retirement and Consulting Agreement dated February 4, 2026. From the retirement date through December 31, 2026, he will provide consulting services for a $10,000 monthly retainer, helping transition his responsibilities.
Under the agreement, Dr. Anwer will receive accrued but unpaid salary and reimbursable expenses within 30 days after his retirement date, plus continued payment of his base salary as severance for twelve months and company-paid COBRA coverage for twelve months. These benefits are conditioned on a customary release of claims in Imunon’s favor.
Imunon, Inc. reported that interim Chief Financial Officer Kimberly Graper will resign from her role effective January 14, 2026 to pursue another career opportunity. The company noted that her departure does not involve any disagreements with management and allows time for an orderly transition.
Imunon appointed Jeffrey Church, its former Executive Vice President, Chief Financial Officer and Corporate Secretary, as interim Chief Financial Officer and as its principal financial and accounting officer effective the same date. His amended consulting arrangement provides a $30,000 monthly retainer plus $250 for each hour of work above 40 hours per month during an extended consulting period that can be ended on 10 business days’ notice.
Imunon, Inc. furnished an 8‑K stating it issued a press release reporting financial results for the quarter ended September 30, 2025. The release is attached as Exhibit 99.1 and, consistent with Item 2.02, the information is furnished and not deemed filed under the Exchange Act or Securities Act.
The company also referenced a conference call scheduled for November 13, 2025, announced on November 6, 2025, with a live webcast available at http://www.imunon.com.
Imunon, Inc. reports that it has received written notice from a Nasdaq Hearings Panel that the company has regained compliance with the $1.00 minimum closing bid price requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2).
This confirms that Imunon’s common stock, trading under the symbol IMNN, currently meets this key Nasdaq standard and removes the immediate listing risk tied specifically to its share price, as long as the company continues to satisfy applicable Nasdaq rules.
Event summary: On August 5, 2025 Imunon, Inc. (IMNN) furnished a press release reporting financial results for the quarter ended June 30, 2025 as Exhibit 99.1. The company had announced on July 29, 2025 that it would hold a conference call on August 5, 2025 to discuss those results; the call was webcast at http://www.imunon.com.
The 8-K clarifies the furnished information is not "filed" under Section 18 of the Exchange Act and contains forward-looking statements subject to a cautionary note in the press release. Exhibits listed are 99.1 (press release) and 104 (Interactive Data). The report is signed by CFO Kimberly Graper and lists principal offices at 997 Lenox Drive, Suite 100, Lawrenceville, NJ 08648-2311 with phone (609) 896-9100.
Imunon, Inc. filed a Form 8-K on 28 Jul 2025 reporting that its Board of Directors has approved a 15% stock dividend, equal to 0.15 additional shares for every outstanding share and each common-stock equivalent with dividend rights. The Board set 7 Aug 2025 as the record date and 21 Aug 2025 as the payment date. Exhibit 99.1 contains the related press release; no other material events, financial results, or transactions were disclosed. The information in the exhibit is furnished, not filed, under the Exchange Act.
Imunon, Inc. filed a Form 8-K reporting that it amended its Certificate of Incorporation to implement a 1-for-15 reverse stock split of its common stock. The Certificate of Amendment was filed on 21 Jul 2025 and the split becomes effective 25 Jul 2025 at 12:01 a.m. ET.
At the effective time, every fifteen pre-split shares will be combined into one post-split share, reducing the number of outstanding shares from approximately 31.8 million to 2.1 million. Authorized share counts, par value and voting rights remain unchanged. Post-split shares will continue trading on Nasdaq under ticker IMNN with a new CUSIP 15117N701.
No fractional shares will be issued; stockholders otherwise entitled to fractions will receive one whole post-split share. Equiniti Trust Company is the exchange agent. Book-entry holders need not act; broker-held positions adjust automatically. The share reduction is proportionally reflected in all active S-1, S-3 and S-8 registration statements pursuant to Rule 416(b).